Variable frequency drives (VFDs) are used in many industrial applications to improve energy efficiency and provide precise ...

Mumbai: Two major infrastructure projects Phase 2 of the Metro-3 corridor and the final phase of the Samruddhi Expressway most likely to be opened to the public on May 1st According to sources ...

That's because it is already in the process of running the ongoing phase 3 LEVEL study and is set to begin the second phase 3 study soon in 2025. Both of these late-stage studies are using this ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data. Arvinas disclosed the rethink alongside news that it is laying off ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. The phase 3 study linked the oral GLP-1 drug orforglipron to similar reductions in blood glucose and body ...

Tamil Nadu Deputy Chief Minister Udhayanidhi Stalin on Thursday (May 1, 2025) inaugurated the work on the third phase of the Chennai Peripheral Ring Road project (CPRR), undertaken by the State ...

Please provide your email address to receive an email when new articles are posted on . Sotyktu significantly improved skin and joint symptoms of psoriatic arthritis and reduced patient-reported ...

Most of us learned to design circuits with schematics. But if you get to a certain level of complexity, schematics are a pain ...

Mark Huffman has been a consumer news reporter for ConsumerAffairs since 2004. He covers real estate, gas prices and the economy and has reported extensively on negative-option sales. He was ...

Guselkumab, an IL-23 inhibitor, is effective in reducing signs, symptoms, and structural damage in active PsA, as confirmed by the APEX study. The FDA approved guselkumab in 2020 based on DISCOVER ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a ...

Today, Johnson & Johnson announced promising new phase 3 data for icotrokinra (JNJ-2113), a first-in-class oral interleukin (IL)-23 receptor antagonist, showing that 75% of adolescents with ...